These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 5026378)

  • 1. Levodopa and pressor amine sensitivity in parkinsonism.
    Reid JL; Calne DB; George CF; Vakil SD
    Clin Pharmacol Ther; 1972; 13(3):400-6. PubMed ID: 5026378
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
    Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R; Kvan L; Presthus J; Thoresen GB
    Acta Neurol Scand Suppl; 1972; 51():121-2. PubMed ID: 4514336
    [No Abstract]   [Full Text] [Related]  

  • 4. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 5. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 6. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
    Miller EM; Wiener L
    Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107
    [No Abstract]   [Full Text] [Related]  

  • 7. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.
    Calne DB; Reid JL; Vakil SD; Rao S; Petrie A; Pallis CA; Gawler J; Thomas PK; Hilson A
    Br Med J; 1971 Sep; 3(5777):729-32. PubMed ID: 4938431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
    Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA
    N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopa-decarboxylase inhibitors.
    Lancet; 1973 May; 1(7810):979-80. PubMed ID: 4121597
    [No Abstract]   [Full Text] [Related]  

  • 10. Interaction between levodopa and methyldopa.
    Gibberd FB; Small E
    Br Med J; 1973 Apr; 2(5858):90-1. PubMed ID: 4573316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentration of levodopa in patients with Parkinson's disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 10(5):301-10. PubMed ID: 4789106
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P
    Acta Neurol Scand Suppl; 1972; 51():111-3. PubMed ID: 4514333
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa in the treatment of Parkinsonism.
    Cotzias GC
    JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
    [No Abstract]   [Full Text] [Related]  

  • 14. Action of L- -methyldopa-hydrazine on the blood pressure of patients receiving levodopa.
    Calne DB; Petrie A; Rao S; Reid JL; Vakil SD
    Br J Pharmacol; 1972 Jan; 44(1):162-4. PubMed ID: 5015036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W; Danielcyk W; Neumayer E; Riederer P
    J Neural Transm; 1973; 34(2):133-43. PubMed ID: 4722571
    [No Abstract]   [Full Text] [Related]  

  • 16. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.
    Marsden CD; Parkes JD; Rees JE
    Lancet; 1973 Dec; 2(7844):1459-62. PubMed ID: 4129310
    [No Abstract]   [Full Text] [Related]  

  • 17. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergism of levodopa by alpha methyldopa.
    Fermaglich J; O'Doherty DS
    Trans Am Neurol Assoc; 1971; 96():231-4. PubMed ID: 5159089
    [No Abstract]   [Full Text] [Related]  

  • 20. [Methyldopa and levodopa].
    Chang CP
    Zhonghua Yi Xue Za Zhi; 1974; 7():439-41. PubMed ID: 4211508
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.